Follow the LILLY ELI & CO stock price and the full insider trade history of the company, a listed equity based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). Market capitalisation: €1,015.5bn. The latest transaction was reported on 8 February 2016 (Cession). Among the most active insiders: Fry Stephen F. Every trade is free.
55
Insider Decl.
n/a
Thresholds
n/a
1 ops.
Buy Volume
n/a
8 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate LILLY ELI & CO Buy (bullish), based on 29 analysts. Average price target: US$1,215.10.
22Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,720 of 28,276 companies
59.2
score / 100
Value
32
Quality
86
FCF yld0.6%
Earn yld2.0%
EV/EBITDA33.7x
ROE107%
Gross mgn83%
Net mgn32%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
LILLY ELI & CO is a company listed on the XNAS market. It is involved in the healthcare sector, focusing on the research and development of pharmaceuticals.